Pegfilgrastim in children with severe congenital neutropenia

Francesca Fioredda; Michaela Calvillo; Marina Lanciotti; Tiziana Lanza; Laura Giunti; Elio Castagnola; Ines Lorenzi; Rossella Tonelli; Piero Ghezzi; Carlo Dufour

doi:10.1002/pbc.22350

Pegfilgrastim in children with severe congenital neutropenia

Francesca Fioredda, Michaela Calvillo, Marina Lanciotti, Tiziana Lanza, Laura Giunti, Elio Castagnola, Ines Lorenzi, Rossella Tonelli, Piero Ghezzi, Carlo Dufour

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.

Original language	English
Pages (from-to)	465-467
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	54
Issue number	3
DOIs	https://doi.org/10.1002/pbc.22350
Publication status	Published - Mar 2010

Keywords

Filgrastim
Pegfilgrastim
R-Hu-granulocyte-stimulating factor
Severe congenital neutropenia

ASJC Scopus subject areas

Hematology
Oncology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1002/pbc.22350

Cite this

Pegfilgrastim in children with severe congenital neutropenia. / Fioredda, Francesca ; Calvillo, Michaela ; Lanciotti, Marina; Lanza, Tiziana; Giunti, Laura; Castagnola, Elio; Lorenzi, Ines; Tonelli, Rossella; Ghezzi, Piero; Dufour, Carlo.

In: Pediatric Blood and Cancer, Vol. 54, No. 3, 03.2010, p. 465-467.

Research output: Contribution to journal › Article › peer-review

@article{204b95a95acb418591dbcb8824ee66dc,

title = "Pegfilgrastim in children with severe congenital neutropenia",

abstract = "Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.",

keywords = "Filgrastim, Pegfilgrastim, R-Hu-granulocyte-stimulating factor, Severe congenital neutropenia",

author = "Francesca Fioredda and Michaela Calvillo and Marina Lanciotti and Tiziana Lanza and Laura Giunti and Elio Castagnola and Ines Lorenzi and Rossella Tonelli and Piero Ghezzi and Carlo Dufour",

year = "2010",

month = mar,

doi = "10.1002/pbc.22350",

language = "English",

volume = "54",

pages = "465--467",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Pegfilgrastim in children with severe congenital neutropenia

AU - Fioredda, Francesca

AU - Calvillo, Michaela

AU - Lanciotti, Marina

AU - Lanza, Tiziana

AU - Giunti, Laura

AU - Castagnola, Elio

AU - Lorenzi, Ines

AU - Tonelli, Rossella

AU - Ghezzi, Piero

AU - Dufour, Carlo

PY - 2010/3

Y1 - 2010/3

N2 - Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.

AB - Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.

KW - Filgrastim

KW - Pegfilgrastim

KW - R-Hu-granulocyte-stimulating factor

KW - Severe congenital neutropenia

UR - http://www.scopus.com/inward/record.url?scp=76749099699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749099699&partnerID=8YFLogxK

U2 - 10.1002/pbc.22350

DO - 10.1002/pbc.22350

M3 - Article

C2 - 19927291

AN - SCOPUS:76749099699

VL - 54

SP - 465

EP - 467

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -

Pegfilgrastim in children with severe congenital neutropenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this